EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of HBeAg chronic hepatitis B with lamivudine vs lamivudine+Interferon A randomized controlled clinical Trial



Treatment of HBeAg chronic hepatitis B with lamivudine vs lamivudine+Interferon A randomized controlled clinical Trial



Journal of Hepatology 34(Supplement 1): 163, April




(PDF same-day service: $19.90)

Accession: 035980440

Download citation: RISBibTeXText

DOI: 10.1016/s0168-8278(01)81472-0



Related references

Higher efficacy of sequential therapy of lamivudine and interferon-A vs lamivudine monotherapy in patients with HBeAg positive chronic hepatitis B A prospective randomized controlled trial. Journal of Hepatology 40(Suppl 1): 131, April, 2004

Treatment of chronic hepatitis D with lamivudine vs lamivudine+interferon vs interferon A randomized controlled clinical trial. Journal of Hepatology 32(Supplement 2): 113, 2000

Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials. Advances in Therapy 24(4): 784-795, 2007

A randomized trial of peginteferon alfa-2b and lamivudine combination treatment versus lamivudine monotherapy in Chinese patients with HBeAg-positive chronic hepatitis B. Journal of Hepatology 40(Suppl 1): 125-126, April, 2004

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Annals of Internal Medicine 142(4): 240-250, 2005

Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. Journal of Microbiology, Immunology, and Infection 38(4): 262-266, 2005

Combination of pegylated interferon and lamivudine is superior to lamivudine monotherapy in the treatment of chronic hepatitis B A randomized Trial. Journal of Hepatology 38(Supplement 2): 33, April, 2003

Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. Journal of Viral Hepatitis 12(3): 262-268, 2005

A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 14(11): 803-805, 2006

Durability of HBeAG seroconversion in chronic hepatitis B patients after lamivudine A-interferon or lamivudine A- interferon combination therapy. Journal of Hepatology 34(Supplement 1): 155, April, 2001

Comparison of lamivudine monotherapy with lamivudine plus interferon alpha combination in patients with HBeAg positive chronic hepatitis B. Journal of Hepatology 34(Supplement 1): 177-178, April, 2001

Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials. Hepatobiliary & Pancreatic Diseases International 9(5): 462-472, 2011

Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World Journal of Gastroenterology 11(37): 5882-5887, 2005

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monoteraphy in patients with chronic hepatitis B A multicenter, randomized Trial. Journal of Hepatology 34(Supplement 1): 136, April, 2001